Primary prevention of diabetes mellitus type 2

被引:0
作者
Gallwitz, B [1 ]
机构
[1] Univ Tubingen, Med Klin 4, D-72076 Tubingen, Germany
来源
INTERNIST | 2004年 / 45卷
关键词
diabetes prevention; impaired glucose tolerance; metformin; acarbose; life style intervention;
D O I
10.1007/s00108-004-1214-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The increasing incidence of type 2 diabetes constitutes a considerable individual and socio-economic risk, therefore preventive concepts are urgently needed. Three prospective studies show that a "life-style-intervention" as well as drugs can prevent the development of diabetes as well as cardiovascular complications: The Diabetes Prevention Study (DPS) evaluated,the influence of a "life-style-intervention" The Diabetes Prevention Program (DPP) additionally examined the effect of metformin. In the Stop-NIDDM-Study acarbose was used for diabetes prevention and cardiovascular endpoints were also evaluated. The incidence of type 2 diabetes can be significantly reduced by a "life-style-intervention" and also by the administration of metformin or acarbose. With acarbose cardiovascular events are reduced significantly and comparably to a therapy with statins in primary prevention.
引用
收藏
页码:S15 / +
页数:7
相关论文
共 23 条
[1]  
[Anonymous], 2000, Diabetes Care, V23, P1619
[2]  
[Anonymous], 1999, Diabetologia, V42, P647
[3]   High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men -: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study [J].
Balkau, B ;
Shipley, M ;
Jarrett, RJ ;
Pyörälä, K ;
Pyörälä, M ;
Forhan, A ;
Eschwège, E .
DIABETES CARE, 1998, 21 (03) :360-367
[4]  
Borch-Johnsen K, 1999, LANCET, V354, P617
[5]   The STOP-NIDDM Trial -: An international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance:: rationale, design, and preliminary screening data [J].
Chiasson, JL ;
Gomis, R ;
Hanefeld, M ;
Josse, RG ;
Karasik, A ;
Laakso, M .
DIABETES CARE, 1998, 21 (10) :1720-1725
[6]   Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
LANCET, 2002, 359 (9323) :2072-2077
[7]   Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance - The STOP-NIDDM Ttrial [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (04) :486-494
[8]   Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population - The Hoorn study [J].
de Vegt, F ;
Dekker, JM ;
Jager, A ;
Hienkens, E ;
Kostense, PJ ;
Stehouwer, CDA ;
Nijpels, G ;
Bouter, LM ;
Heine, RJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (16) :2109-2113
[9]   Contraindications to metformin therapy in patients with Type 2 diabetes - a population-based study of adherence to prescribing guidelines [J].
Emslie-Smith, AM ;
Boyle, DIR ;
Evans, JMM ;
Sullivan, F ;
Morris, AD .
DIABETIC MEDICINE, 2001, 18 (06) :483-488
[10]   Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study [J].
Hanefeld, M ;
Koehler, C ;
Henkel, E ;
Fuecker, K ;
Schaper, F ;
Temelkova-Kurktschiev, T .
DIABETIC MEDICINE, 2000, 17 (12) :835-840